SmithKline Beecham's Paxil
Supplemental NDA for generalized anxiety disorder is filed April 28. The company says that paroxetine is the first selective serotonin reuptake inhibitor submitted to the FDA for the treatment of GAD, which affects an estimated 14 mil. Americans. The condition is characterized by exaggerated tension and worry that interfere with daily function for at least six months
You may also be interested in...
GlaxoSmithKline will present results from a 32-week study of Paxil in relapse prevention of generalized anxiety disorder at the American Psychiatric Association annual meeting in New Orleans May 5-10.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011